Moderna CEO Stéphane Bancel said the Trump administration was a key part of accelerating the company's progress in developing the vaccine.
Moderna's Israeli chief medical officer said Monday that Israel would be among the first countries in line to receive its coronavirusvaccine, hours after the U.S. company announced initial results showing the vaccine is 94.5 percent effective.
The DAK president said COVID-19 vaccine is a two-dose schedule with the second dose to be given 21 days after the first dose. Russian Federation licensed its Sputnik-V COVID-19 vaccine for domestic use in August before it started large-scale trials.
Because of the similarity in approaches, many experts were anticipating the two vaccines would see similar efficacy rates.
"That should give us all hope that actually a vaccine is going to be able to stop this pandemic and hopefully get us back to our lives", Hoge told the Associated Press.
It won't be Moderna alone that solves this problem, he said. Both cautions apply to Pfizer's vaccine as well. Moderna received $2.5 billion from the US government to support research, development and manufacturing of its vaccine candidate, whereas Pfizer signed a contract to sell doses to the USA government.
COVID-19 cases continue to soar across the country, which entered the second wave of the virus in September, according to the prime minister. Only five infections occurred in volunteers who received the vaccine mRNA-1273, which is administered in two shots 28 days apart.
We still need to know more about its safety: But even if the 94.5% efficacy rating holds, a big concern with any vaccine is safety. "This is a really strong step forward to where we want to be".
Moderna expects to have enough safety data required for U.S. authorisation in the next week or so and the company expects to file for emergency use authorisation (EUA) in the coming weeks. The benchmark S&P 500 rose 1%, while the pan-European STOXX 600 climbed 1.3%.
"The vaccine which is based on a novel technology that uses synthetic messenger RNA to activate the immune system against the virus needs to be kept at minus 70 degree Celsius or below to ensure that the vaccine remains potent and safe". Moderna announced Monday that, once thawed, its doses can last longer in a refrigerator than initially thought, up to 30 days.
Prof Van-Tam had compared the Pfizer vaccine trial results to a goal in a penalty shoot-out and he continued the comparison following the Moderna data.
All 11 cases occurred in the placebo group and none in the group which had received the vaccine, known now as mRNA-1273.
"I can announce that we have today secured an initial agreement for five million doses of the Moderna vaccine".
"Assuming we get an emergency use authorisation, we'll be ready to ship through Warp Speed nearly in hours", Hoge said. "So it could start being distributed instantly".
The 95 cases included 15 adults aged 65 or over, and 20 participants from diverse communities including 12 people who identified as Hispanic, 4 Black Americans, 3 Asian Americans and 1 person who was multiracial.
Epidemiologist Dr. Abdu Sharkawy said the news about vaccine trials should be treated for what it is, a light at the end of the tunnel and not an excuse to eschew public health measures.
The news comes exactly a week after similar results from Pfizer and BioNTech, which announced broadly similar results.
In terms of biomanufacturing, Anand said that contracts have been signed to set up what are called "fill and finish" machines to mass-produce doses in Canada. With a pandemic raging, companies are more likely to quickly find an answer about whether the vaccines work or not. Most complaints were short-lived.
Moderna also said it would use its data to seek authorisation in Europe and other regions. Both the Moderna and Pfizer shots are frozen, but at different temperatures.
Other countries such as China and Russian Federation have already begun vaccinations.
However, think about this. a reported 30 percent of Americans don't trust a vaccine, and won't take it.